# Stark Novus Financial Inc.: financial statements, quarterly

SNFI · OTC · CIK 1759546 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/snfi.md) · [Financials](/companies/snfi/financials.md) · [Filings](/companies/snfi/filings.md) · [Insiders](/companies/snfi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/snfi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001558370-24-015438.md) | [0.0 d](/filings/0001641172-25-001195.md) | not reported | not reported | [0.0 d](/filings/0001558370-24-015438.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | [0.0 d](/filings/0001558370-24-015438.md) | [0.0 d](/filings/0001641172-25-001195.md) | not reported | not reported | [0.0 d](/filings/0001558370-24-015438.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.7](/filings/0001558370-24-015438.md) | [0.9 d](/filings/0001641172-25-001195.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | [5.2](/filings/0001641172-25-010257.md) | [1.5](/filings/0001493152-25-011849.md) | [2.3](/filings/0001493152-25-022090.md) | [3.9 d](/filings/0001493152-26-013005.md) | [1.9](/filings/0001493152-26-023856.md) | [1.7](/filings/0001493152-26-038484.md) | [1.2](/filings/0001493152-25-022090.md) | [1.9 d](/filings/0001493152-26-013005.md) | [1.5](/filings/0001493152-26-023856.md) | [1.6](/filings/0001493152-26-038484.md) |
| Operating income | $m | [(17.5)](/filings/0001558370-24-015438.md) | [(3.6) d](/filings/0001641172-25-001195.md) | [(9.5)](/filings/0001641172-25-010257.md) | [0.5](/filings/0001493152-25-011849.md) | [(0.5)](/filings/0001493152-25-022090.md) | [(1.4) d](/filings/0001493152-26-013005.md) | [(1.8)](/filings/0001493152-26-023856.md) | [(0.4)](/filings/0001493152-26-038484.md) | [0.4](/filings/0001493152-25-022090.md) | [(2.1) d](/filings/0001493152-26-013005.md) | [(0.7)](/filings/0001493152-26-023856.md) | [(1.6)](/filings/0001493152-26-038484.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(16.5)](/filings/0001558370-24-015438.md) | [(0.3) d](/filings/0001641172-25-001195.md) | [(8.5)](/filings/0001641172-25-010257.md) | [1.5](/filings/0001493152-25-011849.md) | [0.3](/filings/0001493152-25-022090.md) | [(1.5) d](/filings/0001493152-26-013005.md) | [(1.2)](/filings/0001493152-26-023856.md) | [0.7](/filings/0001493152-26-038484.md) | [1.0](/filings/0001493152-25-022090.md) | [(1.1) d](/filings/0001493152-26-013005.md) | [(0.1)](/filings/0001493152-26-023856.md) | [(1.1)](/filings/0001493152-26-038484.md) |
| Diluted EPS | $ per share | [(1.03)](/filings/0001558370-24-015438.md) | not reported | [(0.57)](/filings/0001641172-25-010257.md) | [0.05](/filings/0001493152-25-011849.md) | [(0.02)](/filings/0001493152-25-022090.md) | not reported | [(0.12)](/filings/0001493152-26-023856.md) | [0.00](/filings/0001493152-26-038484.md) | [0.01](/filings/0001493152-25-022090.md) | not reported | [(0.05)](/filings/0001493152-26-023856.md) | [(0.11)](/filings/0001493152-26-038484.md) |
| Basic EPS | $ per share | [(1.03)](/filings/0001558370-24-015438.md) | not reported | [(0.57)](/filings/0001641172-25-010257.md) | [0.05](/filings/0001493152-25-011849.md) | [(0.02)](/filings/0001493152-25-022090.md) | not reported | [(0.12)](/filings/0001493152-26-023856.md) | [0.00](/filings/0001493152-26-038484.md) | [0.01](/filings/0001493152-25-022090.md) | not reported | [(0.05)](/filings/0001493152-26-023856.md) | [(0.11)](/filings/0001493152-26-038484.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [93.7](/filings/0001558370-23-019031.md) | [87.1](/filings/0001641172-25-001195.md) | [19.7](/filings/0001558370-24-008150.md) | [20.9](/filings/0001558370-24-012064.md) | [26.1](/filings/0001558370-24-015438.md) | [23.1](/filings/0001493152-26-013005.md) | [28.0](/filings/0001641172-25-010257.md) | [26.8](/filings/0001493152-25-011849.md) | [18.2](/filings/0001493152-25-022090.md) | [34.4](/filings/0001493152-26-038484.md) | [25.1](/filings/0001493152-26-023856.md) | [21.5](/filings/0001493152-26-038484.md) |
| Current assets | $m | [101](/filings/0001558370-23-019031.md) | [92.1](/filings/0001641172-25-001195.md) | [79.1](/filings/0001558370-24-008150.md) | [63.7](/filings/0001558370-24-012064.md) | [58.3](/filings/0001558370-24-015438.md) | [53.2](/filings/0001493152-26-013005.md) | [51.5](/filings/0001641172-25-010257.md) | [49.7](/filings/0001493152-25-011849.md) | [48.6](/filings/0001493152-25-022090.md) | [44.8](/filings/0001493152-26-038484.md) | [35.4](/filings/0001493152-26-023856.md) | [32.2](/filings/0001493152-26-038484.md) |
| Total assets | $m | [108](/filings/0001558370-23-019031.md) | [92.2](/filings/0001641172-25-001195.md) | [79.1](/filings/0001558370-24-008150.md) | [63.7](/filings/0001558370-24-012064.md) | [58.3](/filings/0001558370-24-015438.md) | [53.2](/filings/0001493152-26-013005.md) | [51.5](/filings/0001641172-25-010257.md) | [49.7](/filings/0001493152-25-011849.md) | [48.6](/filings/0001493152-25-022090.md) | [47.0](/filings/0001493152-26-038484.md) | [44.2](/filings/0001493152-26-023856.md) | [43.8](/filings/0001493152-26-038484.md) |
| Current liabilities | $m | [22.6](/filings/0001558370-23-019031.md) | [15.4](/filings/0001641172-25-001195.md) | [11.1](/filings/0001558370-24-008150.md) | [1.7](/filings/0001558370-24-012064.md) | [1.8](/filings/0001558370-24-015438.md) | [1.1](/filings/0001493152-26-013005.md) | [0.9](/filings/0001641172-25-010257.md) | [0.8](/filings/0001493152-25-011849.md) | [1.0](/filings/0001493152-25-022090.md) | [1.0](/filings/0001493152-26-038484.md) | [0.6](/filings/0001493152-26-023856.md) | [0.8](/filings/0001493152-26-038484.md) |
| Total liabilities | $m | [62.2](/filings/0001558370-23-019031.md) | [45.9](/filings/0001641172-25-001195.md) | [38.0](/filings/0001558370-24-008150.md) | [21.1](/filings/0001558370-24-012064.md) | [15.2](/filings/0001558370-24-015438.md) | [10.9](/filings/0001493152-26-013005.md) | [10.4](/filings/0001641172-25-010257.md) | [8.4](/filings/0001493152-25-011849.md) | [6.2](/filings/0001493152-25-022090.md) | [6.0](/filings/0001493152-26-038484.md) | [3.2](/filings/0001493152-26-023856.md) | [3.4](/filings/0001493152-26-038484.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [13.7](/filings/0001558370-24-015438.md) | [13.5](/filings/0001493152-26-013005.md) | [7.7](/filings/0001493152-25-011849.md) | [8.5](/filings/0001493152-25-022090.md) | [8.2](/filings/0001493152-25-022090.md) | [6.8](/filings/0001493152-26-038484.md) | [4.9](/filings/0001493152-26-038484.md) | [4.4](/filings/0001493152-26-038484.md) | [4.8](/filings/0001493152-25-022090.md) | [2.6](/filings/0001493152-26-038484.md) | [1.9](/filings/0001493152-26-038484.md) | [0.4](/filings/0001493152-26-038484.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(44.3) d](/filings/0001558370-24-015438.md) | [(17.2) d](/filings/0001641172-25-001195.md) | [(9.6)](/filings/0001641172-25-010257.md) | [(15.2) d](/filings/0001493152-25-011849.md) | [(5.2) d](/filings/0001493152-25-022090.md) | [(5.1) d](/filings/0001493152-26-013005.md) | [(1.8)](/filings/0001493152-26-023856.md) | [(2.1) d](/filings/0001493152-26-038484.md) | [(1.7) d](/filings/0001493152-25-022090.md) | [(1.6) d](/filings/0001493152-26-013005.md) | [(2.6)](/filings/0001493152-26-023856.md) | [(0.9) d](/filings/0001493152-26-038484.md) |
| Capital expenditure | $m | [(0.0) d](/filings/0001558370-24-015438.md) | [0.0 d](/filings/0001641172-25-001195.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.1](/filings/0001558370-23-019031.md) | [16.0](/filings/0001558370-24-008150.md) | [15.9](/filings/0001558370-24-012064.md) | [16.0](/filings/0001558370-24-015438.md) | [0.0](/filings/0001641172-25-010257.md) | [0.0](/filings/0001493152-25-011849.md) | [0.0](/filings/0001493152-25-022090.md) | [16.1](/filings/0001493152-26-023856.md) | [17.5](/filings/0001493152-26-038484.md) | [0.0](/filings/0001493152-25-022090.md) | [16.1](/filings/0001493152-26-023856.md) | [16.1](/filings/0001493152-26-038484.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,289,293 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038484.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.